Results26 Sep 2018 10:05
Going buy the 15th May rns.....
Quote:
Unaudited Revenues in the year ended 31 March 2018 increased by 100% to £6.2m (2017: £3.1m), with the majority of growth from outside of Europe
· Test volumes for non-invasive prenatal testing ("NIPT") more than doubled to over 50,000 (2017: 24,500)
· Operating costs effectively managed to achieve a breakeven EBITDA run-rate in NIPT
End quotes: